CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery

DISEASE CHARACTERISTICS:

• Histologically confirmed early operable adenocarcinoma of the breast
• No evidence of invasive lobular breast disease
• Measurable disease, defined as at least 1 lesion ≥ 2 cm by MRI
• Measurable levels of total choline according to institutional criteria by magnetic resonance spectroscopy
• Must have available or scheduled core breast biopsy procedure
• Hormone receptor status not specified

PATIENT CHARACTERISTICS:

• Menopausal status not specified
• ECOG performance status 0-1
• Platelet count ≥ 100,000/mm^³
• Neutrophil count ≥ 1,500/mm³
• Creatinine < 1.5 times upper limit of normal (ULN)
• Bilirubin < 1.5 times ULN
• ALT and AST < 2.5 times ULN
• Fertile patients must use adequate barrier method contraception during and for at least 150 days after completion of study treatment
• Ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures
• No known hypersensitivity to monoclonal antibodies
• No prior or active malignancies other than curatively treated in situ carcinoma of the cervix, uterus, or basal cell or squamous cell carcinoma of the skin
• No serious uncontrolled medical disorder or active infection that would impair the ability to receive study treatment
• No significant active cardiac disease including any of the following:
• Uncontrolled high blood pressure (i.e., systolic blood pressure [BP] > 160 mm Hg and diastolic BP > 95 mm Hg)
• Unstable angina
• Deep venous thrombosis
• Pulmonary embolism
• Cerebrovascular attack
• Valvular disease
• Congestive heart failure
• Myocardial infarction with the past 6 months
• Serious cardiac arrhythmias
• No dementia or significantly altered mental status that would limit the understanding or rendering of informed consent and compliance with study requirements

PRIOR CONCURRENT THERAPY:

• More than 4 weeks since prior surgery and recovered
• More than 2 weeks since high-dose corticosteroid therapy (i.e., ≥ 100 mg prednisone per day or > 40 mg dexamethasone per day)
• No prior anti-IGF-1R based investigational therapy
• No prior systemic therapy for primary disease
• No concurrent chronic systemic high-dose immunosuppressive steroid therapy
• Low-dose steroids for nausea and vomiting control allowed
• Topical corticosteroid applications, inhaled sprays, eye drops or local injections (e.g., intraocular) allowed
• No concurrent other anticancer drugs or therapy